YAP1调控lncRNA的m6A修饰而促进结肠癌侵袭转移的机制
批准号:
82073261
项目类别:
面上项目
资助金额:
57.0 万元
负责人:
马健
依托单位:
学科分类:
肿瘤复发与转移
结题年份:
2024
批准年份:
2020
项目状态:
已结题
项目参与者:
马健
中文摘要
Hippo-YAP通路与肿瘤发生发展的关系非常密切。我们前期发现,YAP1是结肠癌中重要的癌基因。YAP1调控的下游靶分子中除了基因之外,还有lncRNA。YAP1可通过下游的linc00152、MALAT1而促进结肠癌细胞的增殖与侵袭转移。我们新近发现YAP1可调控细胞m6A修饰谱,可与m6A writer METTL3结合,m6A修饰的RNA可促进YAP1入核并与METTL3结合。基于此,我们提出科学假设,YAP1可通过调控lncRNA的m6A修饰,影响lncRNA的代谢,发挥一系列生物学效应,从而促进结肠癌细胞侵袭与转移。我们还将针对该机制设计靶向策略,在小鼠模型中考察是否可抑制结肠癌转移。YAP1调控lncRNA m6A修饰可能是其发挥生理学功能的一个新的途径,研究该途径为结肠癌的转化研究提供新的、重要的研究材料。
英文摘要
The Hippo pathway is a highly conserved signaling pathway across higher-order vertebrates that modulates key target genes to regulate a multitude of biological processes including cellular proliferation, survival, differentiation, cellular fate determination, organ size, and tissue homeostasis. The link between the Hippo pathway and cancer development has been intensively studied in recent years..Yes-associated protein 1 (YAP1) is an effector of Hippo pathway, which is critical for regulating organ size, cell proliferation and tumor growth in mammals. We previous reported the relationship between YAP1 and tumorigenesis and metastasis of colorectal cancer. Positive YAP1 expression can statistically contribute to poor overall survival and disease-free survival in patients with colorectal carcinoma. We identified the downstream genes of YAP1, and found that, besides mRNAs, multiple lncRNAs are regulated by YAP1. .YAP1 can promoter tumorigenesis and metastasis of colorectal cancer through modulating lncRNAs such as linc00152 and MALAT1. Both of them are identified as oncogenic lncRNAs in colorectal cancer. .We recently discovered that YAP1 can modulate the cellular m6A epitranscriptomes of colon cancer cells. YAP1 can interact with METTL3 (a m6A writer) in the cellular nucleus. Adding the m6A modified RNA into the cells can promote YAP1’s location in the nucleus and facilitate its interaction with METTL3..Based on these findings, we suggest a hypothesis in this proposal that YAP1 promotes colon cancer invasion and metastasis through modulating m6A modification of lncRNAs such as linc00152 and MALAT1..In this study, we will dissect the molecular mechanisms underlying how YAP1 modulates the m6A modification of lncRNA, and the effect of this modification on lncRNA metabolism; and how the YAP1-lncRNA axis could promote metastasis of colon cancer cells through controlling FSCN1 and S100A8. Both of them are downstream targets of linc00152. FSCN1 proteins organize F-actin into parallel bundles, and are required for the formation of actin-based cellular protrusions, playing a critical role in cell migration, motility, adhesion and cellular interactions. S100A8 is a cytokine secreted by multiple cells and is crucial for inflammation process as well as tumor metastasis. We will test the effect of targeting the YAP1-lncRNA axis and m6A modification mechanism in mouse model of colon cancer metastasis..This study will provide new insight into the potential use of YAP1-lncRNA and m6 modification for the development of new treatment strategies for colorectal tumorigenesis.
m6A修饰是一种动态的RNA修饰,与癌症发生发展和预后密切相关。.我们前期发现YAP1、TGF-β、NF-κB等多种信号通路皆可促进LINC00152的转录。该分子是一个重要的促癌lncRNA分子,是多条信号通路的中间环节。.本项目发现: LINC00152可显著升高结直肠癌细胞的总m6A水平,促进甲基转移酶复合物METTL3-WTAP-METTL14之间的结合和写入m6A的功能。筛选实验发现LINC00152通过调控靶基因ARHGEF12的m6A甲基化修饰促进ARHGEF12 mRNA的稳定性。联合RNA-seq和meRIP-seq筛选和检测发现:LINC00152显著促进RhoA活性和ROCK2、p-Cofilin和Fascin的表达。ARHGEF12作为RhoA 的特异性GTP交换因子可调控RhoA活性。干扰LINC00152或ARHGEF12表达,导致包括有丝分裂灾难、细胞分裂延迟等表型变化,最终促进肿瘤细胞凋亡。后续将使用脂质纳米颗粒包裹的小干扰 RNA评估靶向LINC00152-m6A-RhoA/ROCK2轴治疗结直肠癌的潜力。并针对新发现的信号通路轴以及在有丝分裂进展的重要作用,评估其靶向治疗以及联合抗纺锤体药物的治疗潜力。.此外,受本项目的资助我们开展了这些围绕着RNA m6A修饰的工作:(1)开发基于胃癌细胞膜的仿生纳米药物递送系统,通过靶向EphA2和METTL3(m6A的写入酶),有效抑制胃癌的生长和转移,增强抗肿瘤免疫反应,为胃癌治疗提供了新策略;(2)EB病毒通过调节宿主细胞的m6A修饰系统抑制TLR9的表达和功能,利于免疫逃逸;而METTL3和YTHDF1在调控TLR9表达和功能中发挥重要作用,可成为治疗EBV相关肿瘤的新靶点;(3)DNA损伤应答中的蛋白激酶ATM被m6A修饰,而METTL3可破坏了ATM的稳定性,从而影响DNA损伤应答。
靶向EB病毒EBNA1、EBNA2相分离抑制鼻咽癌恶性表型的研究
-
批准号:2026JJ30148
-
项目类别:省市级项目
-
资助金额:0.0万元
-
批准年份:2026
-
负责人:马健
-
依托单位:
S100A8诱导PD-L1表达参与肿瘤免疫逃逸的机制
-
批准号:81874170
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2018
-
负责人:马健
-
依托单位:
乳铁蛋白调控肿瘤微环境的机制研究
-
批准号:81672889
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2016
-
负责人:马健
-
依托单位:
microRNA分子参与肿瘤细胞上皮-间质转化过程中鲁棒性维持的分子机制
-
批准号:81472694
-
项目类别:面上项目
-
资助金额:72.0万元
-
批准年份:2014
-
负责人:马健
-
依托单位:
乳铁蛋白抗EB病毒感染的机制及其与鼻咽癌变的关系
-
批准号:81171988
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:马健
-
依托单位:
LTF抑制鼻咽癌侵袭转移的分子机制研究
-
批准号:81071756
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2010
-
负责人:马健
-
依托单位:
一个候选细胞黏附分子的鉴定
-
批准号:30300064
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2003
-
负责人:马健
-
依托单位:
国内基金
海外基金